Magnesium Sulfate Versus Ipratropuim Bromide in Acute Exacerbation of Chronic Obstructive Pulmonary Disease
COPD Exacerbation
About this trial
This is an interventional treatment trial for COPD Exacerbation focused on measuring COPD exacerbation, Magnesium sulfate, Ipratropium bromide, Emergency departement
Eligibility Criteria
Inclusion Criteria:
- 40 years old or over
- have known or suspected COPD based on pulmonary function test, arterial blood gas, clinical history, physical examination, and chest radiograph
- worsening of dyspnea within 2 weeks,
- partial pressure of arterial carbon dioxide (PaCO2) >45 mmHg
- respiratory rate >24/min
- arterial pH <7.35
- partial pressure of arterial oxygen (PaO2) <50 mmHg under room air
Exclusion Criteria:
- hypersensitivity to anticholinergics and to magnesium sulfate
- patients that received anticholinergics within 6 hours before ED admission
- systolic arterial pressure <90 mmHg or need to vasoactive drugs
Sites / Locations
- University Hospital of Monastir
- Soudani Marghli
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Ipratropium bromide
Magnesium sulfate
Patients received ipratropium bromide (IB group, 0.5 mg in 3 mL of normal saline) delivered via aerosol mask at 10 L/min driven by pressurised air. Simultaneously, patients received intravenous placebo (10 mL of normal saline). Thereafter 4 doses of nebulised IB with terbutaline are administered at 30 min intervals.
Patients received magnesium sulfate (MgSO4 group, 150 mg in 4 mL of normal saline)delivered via aerosol mask at 10 L/min driven by pressurised air. Simultaneously, additional magnesium sulfate is given as an intravenous bolus (1.5g in 10 ml). Patients received thereafter 4 doses of nebulized magnesium sulfate with terbutaline at 30 min intervals.